{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:54:49Z","timestamp":1770069289059,"version":"3.49.0"},"reference-count":99,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>New developments in the epidemiology, treatment and prognosis of thalassemia have dramatically altered the approach to the care of affected patients, and these developments are likely to have an even greater impact in the next few years. Demographic changes have required an awareness and understanding of the unique features of thalassemia disorders that were previously uncommon in North America but are now seen more frequently in children and recognized more consistently in adults. New methods for measuring tissue iron accumulation and new drugs to remove excessive iron are advancing two of the most challenging areas in the management of thalassemia as well as other transfusion-dependent disorders. Improved survival of patients with thalassemia has given new importance to adult complications such as endocrinopathies and hepatitis that have a major impact on the quality of life. This chapter describes how these changes are redefining the clinical management of thalassemia.<\/jats:p>\n               <jats:p>In Section I, Dr. Renzo Galanello describes recent advances in iron chelation therapy. Several new chelators are either licensed in some countries, are in clinical trials or are in the late stages of preclinical development. Some of these iron chelators, such as deferiprone (DFP) and ICL670, are orally active. Others, such as hydroxybenzyl-ethylenediamine-diacetic acid (HBED) and starch deferoxamine, require parenteral administration but may be effective with less frequent administration than is currently required for deferoxamine. Chelation therapy employing two chelators offers the possibility of more effective removal of iron without compromising safety or compliance. Other strategies for chelation therapy may take advantage of the ability of particular chelators to remove iron from specific target organs such as the heart and the liver.<\/jats:p>\n               <jats:p>In Section II, Dr. Dudley Pennell addresses cardiac iron overload, the most frequent cause of death from chronic transfusion therapy. The cardiac complications related to excessive iron may result from long-term iron deposition in vulnerable areas or may be due to the more immediate effects of nontransferrin-bound iron. Cardiac disease is reversible in some patients with intensive iron chelation therapy, but identification of cardiac problems prior to the onset of serious arrhythmias or congestive heart failure has proven difficult. New methods using magnetic resonance imaging (MRI) have recently been developed to assess cardiac iron loading, and studies suggest a clinically useful relationship between the results using these techniques and critical measures of cardiac function. Measurements such as T2* may help guide chelation therapy in individual patients and may also enhance the assessment of new chelators in clinical trials. The use of MRI-based technology also holds promise for wider application of non-invasive assessment of cardiac iron in the management of patients with thalassemia.<\/jats:p>\n               <jats:p>In Section III, Dr. Melody Cunningham describes some of the important complications of thalassemia that are emerging as patients survive into adulthood. Hepatitis C infection is present in the majority of patients older than 25 years. However, antiviral therapy in patients with thalassemia has been held back by the absence of large clinical trials and concern about ribavirin-induced hemolysis. More aggressive approaches to the treatment of hepatitis C may be particularly valuable because of the additive risks for cirrhosis and hepatocellular carcinoma that are posed by infection and iron overload. Thrombosis is recognized with increasing frequency as a significant complication of thalassemia major and thalassemia intermedia, and pulmonary hypertension is now the focus of intense study. Risk factors for thrombosis such as splenectomy are being identified and new approaches to anticoagulation are being initiated. Pregnancies in women with thalassemia are increasingly common with and without hormonal therapy, and require a better understanding of the risks of iron overload and cardiac disease in the mother and exposure of the fetus to iron chelators.<\/jats:p>\n               <jats:p>In Section IV, Dr. Elliott Vichinsky describes the dramatic changes in the epidemiology of thalassemia in North America. Hemoglobin E-\u03b2 thalassemia is seen with increasing frequency and poses a particular challenge because of the wide variability in clinical severity. Some affected patients may require little or no intervention, while others need chronic transfusion therapy and may be appropriate candidates for hematopoietic stem cell transplantation. Enhancers of fetal hemoglobin production may have a unique role in Hb E-\u03b2 thalassemia since a modest increase in hemoglobin level may confer substantial clinical benefits. Alpha thalassemia is also being recognized with increasing frequency in North America, and newborn screening for Hemoglobin Barts in some states is leading to early detection of Hb H disease and Hb H Constant Spring. New data clarify the importance of distinguishing these two disorders because of the increased severity associated with Hb H Constant Spring. The use of intrauterine transfusions to sustain the viability of fetuses with homozygous alpha thalassemia has created a new population of patients with severe thalassemia and has raised new and complex issues in genetic counseling for parents with alpha thalassemia trait.<\/jats:p>","DOI":"10.1182\/asheducation-2004.1.14","type":"journal-article","created":{"date-parts":[[2004,11,19]],"date-time":"2004-11-19T21:03:01Z","timestamp":1100898181000},"page":"14-34","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":162,"title":["Thalassemia"],"prefix":"10.1182","volume":"2004","author":[{"given":"Alan R.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Galanello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dudley J.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody J.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott","family":"Vichinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021215281213800_R1","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major [abstract]. Cooley\u2019s Anemia-Seventh Symposium. 1998;850:227."},{"key":"2020021215281213800_R2","doi-asserted-by":"crossref","unstructured":"Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program).2003:46\u201352.","DOI":"10.1182\/asheducation-2003.1.40"},{"key":"2020021215281213800_R3","doi-asserted-by":"crossref","unstructured":"Cunningham MJ, Acklin EA, Neufeld EJ, Cohen R. Complications of thalassemia major North America. Blood.February 26, 2004; e-pub ahead of print. DOI 10.1182\/blood-2003-09-3167.","DOI":"10.1182\/blood-2003-09-3167"},{"key":"2020021215281213800_R4","doi-asserted-by":"crossref","unstructured":"Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in ion overload: redox activity and susceptibility to chelation. Blood. 2003;102:2670\u20132677.","DOI":"10.1182\/blood-2003-03-0807"},{"key":"2020021215281213800_R5","doi-asserted-by":"crossref","unstructured":"Hider RC, Liu ZD. Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload. Curr Med Chem. 2003;10:1051\u20131064.","DOI":"10.2174\/0929867033457629"},{"key":"2020021215281213800_R6","doi-asserted-by":"crossref","unstructured":"Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17\u201322.","DOI":"10.1182\/blood-2002-06-1867"},{"key":"2020021215281213800_R7","doi-asserted-by":"crossref","unstructured":"Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br. J Haematol. 2000;108:305\u2013312.","DOI":"10.1046\/j.1365-2141.2000.01866.x"},{"key":"2020021215281213800_R8","unstructured":"Piga A, Caglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489\u2013496."},{"key":"2020021215281213800_R9","doi-asserted-by":"crossref","unstructured":"Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell D. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet. 2002;360:516\u2013520.","DOI":"10.1016\/S0140-6736(02)09740-4"},{"key":"2020021215281213800_R10","doi-asserted-by":"crossref","unstructured":"Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003; 10:1065\u20131076.","DOI":"10.2174\/0929867033457610"},{"key":"2020021215281213800_R11","doi-asserted-by":"crossref","unstructured":"Brittenham GM. Iron chelators and iron toxicity. Alcohol. 2003;30:151\u2013158.","DOI":"10.1016\/S0741-8329(03)00101-0"},{"key":"2020021215281213800_R12","doi-asserted-by":"crossref","unstructured":"Grady RW, Sable AD, Hilgartner MW, et al. Results from a phase I clinical trial of HBED. Adv Exp Med Biol. 1994;356:351\u2013359.","DOI":"10.1007\/978-1-4615-2554-7_37"},{"key":"2020021215281213800_R13","doi-asserted-by":"crossref","unstructured":"Bergeron RJ, Wiegand J, Brittenham GM. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood. 2002;99:3019.","DOI":"10.1182\/blood.V99.8.3019"},{"key":"2020021215281213800_R14","doi-asserted-by":"crossref","unstructured":"Hermes-Lima M, Santos NC, Yan J, Andrews M, Schulman HM, Ponka P. EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on ZOH formation by the Fenton reaction. Biochim Biophys Acta. 1999;1426:475\u2013482.","DOI":"10.1016\/S0304-4165(98)00167-6"},{"key":"2020021215281213800_R15","doi-asserted-by":"crossref","unstructured":"Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron chelation after oral administration. Semin Hematol. 1990;27:112\u2013116.","DOI":"10.1111\/j.1749-6632.1990.tb24319.x"},{"key":"2020021215281213800_R16","doi-asserted-by":"crossref","unstructured":"Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med. 1998;131:306\u2013314.","DOI":"10.1016\/S0022-2143(98)90180-9"},{"key":"2020021215281213800_R17","doi-asserted-by":"crossref","unstructured":"Link G, Ponka P, Konijn AM, Breuer W, Cabantchik I, Hershko C. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and iron-loaded rat heart cells. Blood. 2003;101:4172.","DOI":"10.1182\/blood-2002-08-2382"},{"key":"2020021215281213800_R18","unstructured":"Marquis JK, Aoude-Dagher R, Guillumat PO. Pharmacology and toxicology of GT56-252, a novel orally available iron chelator [abstract]. 12th International Conference on Oral Chelation in the Treatment of Thalassaemia & Other Disease (ICOC Santorini). 2002:112."},{"key":"2020021215281213800_R19","doi-asserted-by":"crossref","unstructured":"Bree MP, Marquis JK, Wagner JL, Bell J. Pharmacodynamics of repeat dose oral administration of GT56-252 in iron-loaded Cebus monkeys [abstract]. Hematology J. 2004;5(suppl 2):S192.","DOI":"10.1038\/sj.thj.6200503"},{"key":"2020021215281213800_R20","unstructured":"Donovan JM, Palmer PA, Plone MA, Wonke B. The safety and pharmacokinetics of GT56-252, a novel orally available iron chelator [abstract]. 38th Annual Meeting of the European Society for Clinical Investigation. Eur J Clin Invest. 2004;139:39."},{"key":"2020021215281213800_R21","unstructured":"Harmatz P, Madden J, Vichinsky E, et al. A phase Ib study of safety, pharmacokinetics, acute tolerability, and efficacy of ascending single doses of 40SD02 (CHF1540) in iron-loaded patients [abstract]. The International BioIron Society World Congress on Iron Metabolism. 2003;54."},{"key":"2020021215281213800_R22","unstructured":"Harmatz P, Grady WB, Vichinsky E, et al. A phase 1b study of safety, pharmacokinetics, acute tolerability, and efficacy of ascending single doses of 40SD02 (CHF1540, GS 460) in iron-loaded patients [abstract]. Blood. 2004;(suppl 1):121a."},{"key":"2020021215281213800_R23","doi-asserted-by":"crossref","unstructured":"Galanello R, Piga A, Alberti D et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003;43:565\u2013572.","DOI":"10.1177\/0091270003253350"},{"key":"2020021215281213800_R24","doi-asserted-by":"crossref","unstructured":"Nisbet-Brown E, Olivieri NF, Giardina PJ et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597\u20131602.","DOI":"10.1016\/S0140-6736(03)13309-0"},{"key":"2020021215281213800_R25","unstructured":"Grady RW, Berdoukas V, Rachmilewitz EA, et al. Iron chelation therapy: metabolic aspects of combining deferiprone and deferoxamine [abstract]. 11th International Conference on Oral Chelation in the Treatment of Thalassaemia Major and Other Disease (Catania). 2001;74\u201378"},{"key":"2020021215281213800_R26","doi-asserted-by":"crossref","unstructured":"Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361\u2013364.","DOI":"10.1046\/j.1365-2141.1998.01002.x"},{"key":"2020021215281213800_R27","doi-asserted-by":"crossref","unstructured":"Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187\u2013189.","DOI":"10.1046\/j.1365-2141.2003.04240.x"},{"key":"2020021215281213800_R28","unstructured":"Galanello R, Doneddu I, Dessi\u2019 E, et al. Iron chelation in thalassemia major: combined treatment with deferiprone and deferoxamine [abstract]. 11th International Conference on Oral Chelation in the Treatment of Thalassaemia and Other Disease (Catania). 2001;Abs:73."},{"key":"2020021215281213800_R29","doi-asserted-by":"crossref","unstructured":"Breuer W, Empers MJJ, Pootrakul P, Abramov A, Hershko C, Cabantchik I. Deferoxamine chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97:792\u2013798.","DOI":"10.1182\/blood.V97.3.792"},{"key":"2020021215281213800_R30","unstructured":"Grady RW, Giardina PJ. Oral iron chelation: a potential role for HBED in combination therapy [abstract]. Blood. 1999;94(Suppl1): #3293."},{"key":"2020021215281213800_R31","doi-asserted-by":"crossref","unstructured":"Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med. 2002;139:50\u201358.","DOI":"10.1067\/mlc.2002.120364"},{"key":"2020021215281213800_R32","doi-asserted-by":"crossref","unstructured":"Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001;97:1115\u20131122.","DOI":"10.1182\/blood.V97.4.1115"},{"key":"2020021215281213800_R33","doi-asserted-by":"crossref","unstructured":"Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632\u20134639.","DOI":"10.1182\/blood-2002-09-2754"},{"key":"2020021215281213800_R34","doi-asserted-by":"crossref","unstructured":"Jensen PD, Jensen FT, Christensen T, Heickendorff L, Jensen LG, Ellegaard J. Indirect evidence for the potential ability of magnetic resonance imaging to evaluate the myocardial iron content in patients with transfusional iron overload. MAGMA. 2001;12:153\u2013166.","DOI":"10.1007\/BF02668097"},{"key":"2020021215281213800_R35","unstructured":"Liu PP, Henkelman M, Joshi J, et al. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassaemia\u2013cardiac iron overload model. Can J Cardiol. 1996;12:155\u2013164"},{"key":"2020021215281213800_R36","doi-asserted-by":"crossref","unstructured":"Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation time study of iron overload in \u03b2-thalassemia. MAGMA. 1998;6:7\u201312.","DOI":"10.1007\/BF02662506"},{"key":"2020021215281213800_R37","doi-asserted-by":"crossref","unstructured":"Anderson LJ, Holden S, Davies B, et al. Cardiovascular T2* (T2 star) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171\u20132179.","DOI":"10.1053\/euhj.2001.2822"},{"key":"2020021215281213800_R38","doi-asserted-by":"crossref","unstructured":"Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18:33\u201339.","DOI":"10.1002\/jmri.10332"},{"key":"2020021215281213800_R39","doi-asserted-by":"crossref","unstructured":"Westwood M, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance in the early diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18:616\u2013620.","DOI":"10.1002\/jmri.10396"},{"key":"2020021215281213800_R40","unstructured":"Westwood MA. Cardiovascular magnetic resonance in myocardial siderosis. MD Thesis. Imperial College, London. 2004. Submitted."},{"key":"2020021215281213800_R41","unstructured":"Anderson LJ. Assessment of cardiac iron overload in thalassaemia. MD Thesis. Imperial College, London. 2002."},{"key":"2020021215281213800_R42","doi-asserted-by":"crossref","unstructured":"Pennell DJ, Bland JM. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet. 2003;361:182\u2013184.","DOI":"10.1016\/S0140-6736(03)12221-0"},{"key":"2020021215281213800_R43","doi-asserted-by":"crossref","unstructured":"Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934\u20131936.","DOI":"10.1182\/blood-2003-06-1919"},{"key":"2020021215281213800_R44","doi-asserted-by":"crossref","unstructured":"Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in beta thalassaemia. Lancet. 2002;360:516\u2013520.","DOI":"10.1016\/S0140-6736(02)09740-4"},{"key":"2020021215281213800_R45","doi-asserted-by":"crossref","unstructured":"Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, The Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104:34\u201339.","DOI":"10.1182\/blood-2003-09-3167"},{"key":"2020021215281213800_R46","doi-asserted-by":"crossref","unstructured":"Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat. 2002;9:390\u2013392.","DOI":"10.1046\/j.1365-2893.2002.00368.x"},{"key":"2020021215281213800_R47","doi-asserted-by":"crossref","unstructured":"Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124:114\u2013117.","DOI":"10.1046\/j.1365-2141.2003.04732.x"},{"key":"2020021215281213800_R48","doi-asserted-by":"crossref","unstructured":"Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35:S86\u2013S91.","DOI":"10.1097\/00004836-200211002-00004"},{"key":"2020021215281213800_R49","doi-asserted-by":"crossref","unstructured":"Fried MW, Shiffman ML, Reddy KR, et al Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975\u2013982.","DOI":"10.1056\/NEJMoa020047"},{"key":"2020021215281213800_R50","doi-asserted-by":"crossref","unstructured":"Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol. 2002;117:755\u2013758.","DOI":"10.1046\/j.1365-2141.2002.03491.x"},{"key":"2020021215281213800_R51","doi-asserted-by":"crossref","unstructured":"Telfer PT, Garson JA, Whitby K, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol. 1997;98:850\u2013855.","DOI":"10.1046\/j.1365-2141.1997.2953112.x"},{"key":"2020021215281213800_R52","unstructured":"Hamidah A, Yong JF, Zulkifli HI, Jamal R. Treatment of chronic hepatitis C virus infection with interferon alfa and ribavirin: sustained response in two patients with transfusion dependent thalassaemia. Med J Malaysia. 2002;57:353\u2013356."},{"key":"2020021215281213800_R53","doi-asserted-by":"crossref","unstructured":"Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99:36\u201343.","DOI":"10.1182\/blood.V99.1.36"},{"key":"2020021215281213800_R54","doi-asserted-by":"crossref","unstructured":"Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111:467\u2013473.","DOI":"10.1046\/j.1365-2141.2000.02376.x"},{"key":"2020021215281213800_R55","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E\/beta-thalassaemic patients. Br J Haematol. 2002;118:893\u2013898.","DOI":"10.1046\/j.1365-2141.2002.03711.x"},{"key":"2020021215281213800_R56","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E\/beta-thalassemia: a consequence of splenectomy. Int J Hematol. 2003;77:299\u2013303.","DOI":"10.1007\/BF02983790"},{"key":"2020021215281213800_R57","doi-asserted-by":"crossref","unstructured":"Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411\u20133416.","DOI":"10.1182\/blood.V97.11.3411"},{"key":"2020021215281213800_R58","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78:139\u2013145.","DOI":"10.1007\/BF02983382"},{"key":"2020021215281213800_R59","doi-asserted-by":"crossref","unstructured":"Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886\u2013895.","DOI":"10.1056\/NEJMoa035477"},{"key":"2020021215281213800_R60","unstructured":"Pafumi C, Farina M, Pernicone G, et al. At term pregnancies in transfusion-dependent beta-thalassemic women. Clin Exp Obstet Gynecol. 2000;27:185\u2013187."},{"key":"2020021215281213800_R61","unstructured":"Skordis N, Christou S, Koliou M, Pavlides N, Angastiniotis M. Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab. 1998;11 Suppl 3:935\u2013943."},{"key":"2020021215281213800_R62","unstructured":"Karagiorga-Lagana M. Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol Metab. 1998;11 Suppl 3:945\u2013951."},{"key":"2020021215281213800_R63","unstructured":"Cunningham MJ, Macklin EA, Muraca G, Neufeld EJ. Successful pregnancy in thalassemia major women in the Thalassemia Clinical Research Network. Pediatr Res. 2004;55:294A."},{"key":"2020021215281213800_R64","doi-asserted-by":"crossref","unstructured":"Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf). 2000;53:33\u201342.","DOI":"10.1046\/j.1365-2265.2000.00962.x"},{"key":"2020021215281213800_R65","doi-asserted-by":"crossref","unstructured":"Chamayou S, Alecci C, Ragolia C, et al. Successful application of preimplantation genetic diagnosis for beta-thalassaemia and sickle cell anaemia in Italy. Hum Reprod. 2002;17:1158\u20131165.","DOI":"10.1093\/humrep\/17.5.1158"},{"key":"2020021215281213800_R66","doi-asserted-by":"crossref","unstructured":"Van de Velde H, Georgiou I, De Rycke M, et al. Novel universal approach for preimplantation genetic diagnosis of beta-thalassaemia in combination with HLA matching of embryos. Hum Reprod. 2004;19:700\u2013708.","DOI":"10.1093\/humrep\/deh153"},{"key":"2020021215281213800_R67","doi-asserted-by":"crossref","unstructured":"Lorey F, Charoenkwan P, Witkowska HE, et al. Hb H hydrops foetalis syndrome: a case report and review of literature. Br J Haematol. 2001;115:72\u201378.","DOI":"10.1046\/j.1365-2141.2001.03080.x"},{"key":"2020021215281213800_R68","doi-asserted-by":"crossref","unstructured":"Lorey F, Cunningham G, Vichinsky EP, et al. Universal newborn screening for Hb H disease in California. Genet Test. 2001;5:93\u2013100.","DOI":"10.1089\/109065701753145538"},{"key":"2020021215281213800_R69","unstructured":"Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79:704\u2013712."},{"key":"2020021215281213800_R70","doi-asserted-by":"crossref","unstructured":"Vichinsky EP. Report of proceedings: International conference on E-B thalassemia. J Pediatr Hematol Oncol. 2000;22:550\u2013601.","DOI":"10.1097\/00043426-200011000-00020"},{"key":"2020021215281213800_R71","doi-asserted-by":"crossref","unstructured":"Lorey F. Asian immigration and public health in California: thalassemia in newborns in California. J Pediatr Hematol Oncol. 2000;22:564\u2013566.","DOI":"10.1097\/00043426-200011000-00024"},{"key":"2020021215281213800_R72","doi-asserted-by":"crossref","unstructured":"Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci. 1998;850:251\u2013269.","DOI":"10.1111\/j.1749-6632.1998.tb10482.x"},{"key":"2020021215281213800_R73","doi-asserted-by":"crossref","unstructured":"Lau YL, Chan LC, Chan YY, et al. Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong \u2014 implications for population screening. N Engl J Med. 1997;336:1298\u20131301.","DOI":"10.1056\/NEJM199705013361805"},{"key":"2020021215281213800_R74","doi-asserted-by":"crossref","unstructured":"de Silva S, Fisher CA, Premawardhena A, et al. Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Sri Lanka Thalassaemia Study Group. Lancet. 2000;355:786\u2013791.","DOI":"10.1016\/S0140-6736(99)08246-X"},{"key":"2020021215281213800_R75","doi-asserted-by":"crossref","unstructured":"Rees DC. Hemoglobin F and hemoglobin E\/beta-thalassemia. J Pediatr Hematol Oncol. 2000;22:567\u2013572.","DOI":"10.1097\/00043426-200011000-00025"},{"key":"2020021215281213800_R76","doi-asserted-by":"crossref","unstructured":"Fucharoen S, Ketvichit P, Pootrakul P, Siritanaratkul N, Piankijagum A, Wasi P. Clinical manifestation of beta-thalassemia\/hemoglobin E disease. J Pediatr Hematol Oncol. 2000;22:552\u2013557.","DOI":"10.1097\/00043426-200011000-00022"},{"key":"2020021215281213800_R77","doi-asserted-by":"crossref","unstructured":"Fisher CA, Premawardhena A, de Silva S, et al. The molecular basis for the thalassaemias in Sri Lanka. Br J Haematol. 2003;121:662\u2013671.","DOI":"10.1046\/j.1365-2141.2003.04346.x"},{"key":"2020021215281213800_R78","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E\/beta-thalassaemic patients. Br J Haematol. 2002;118:893\u2013898.","DOI":"10.1046\/j.1365-2141.2002.03711.x"},{"key":"2020021215281213800_R79","doi-asserted-by":"crossref","unstructured":"Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded {beta}-thalassemia\/HbE patients treated with an oral chelator. Blood. 2004;104:1504\u20131510.","DOI":"10.1182\/blood-2004-02-0630"},{"key":"2020021215281213800_R80","doi-asserted-by":"crossref","unstructured":"Viprakasit V, Tanphaichitr VS, Chinchang W, Sangkla P, Weiss MJ, Higgs DR. Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia. Blood. 2004;103:3296\u20133299.","DOI":"10.1182\/blood-2003-11-3957"},{"key":"2020021215281213800_R81","unstructured":"Pakbaz Z FR, Fung E, Harmatz P, Vichinsky E. Serum Ferritin Underestimates the Liver Iron Concentration. Pediatric Blood and Cancer. 2004;42:497."},{"key":"2020021215281213800_R82","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Chuncharunee S, Chandanamattha P, Likittanasombat K, Aryurachai K. Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E\/beta-thalassemia patient. Blood. 2004;103:2844\u20132846.","DOI":"10.1182\/blood-2003-09-3094"},{"key":"2020021215281213800_R83","doi-asserted-by":"crossref","unstructured":"Unchern S, Laoharuangpanya N, Phumala N, et al. The effects of vitamin E on platelet activity in beta-thalassaemia patients. Br J Haematol. 2003;123:738\u2013744.","DOI":"10.1046\/j.1365-2141.2003.04691.x"},{"key":"2020021215281213800_R84","doi-asserted-by":"crossref","unstructured":"Hough RE, Kelly R, Nakielny R, Winfield DA. Extramedullary haemopoiesis in haemoglobin E\/beta-thalassaemia. Br J Haematol. 2003;120:918.","DOI":"10.1046\/j.1365-2141.2003.04124.x"},{"key":"2020021215281213800_R85","unstructured":"Singer TS KF, Mignacca R, Coates T, Vichinsky E. Red blood cell characteristics in E\/\u03b2 thalassemia and effect of hydroxyurea treatment. Blood. 2001;98:23b."},{"key":"2020021215281213800_R86","doi-asserted-by":"crossref","unstructured":"Chen FE, Ooi C, Ha SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med. 2000;343:544\u2013550.","DOI":"10.1056\/NEJM200008243430804"},{"key":"2020021215281213800_R87","doi-asserted-by":"crossref","unstructured":"Chui DH, Waye JS. Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem. Blood. 1998;91:2213\u20132222.","DOI":"10.1182\/blood.V91.7.2213"},{"key":"2020021215281213800_R88","doi-asserted-by":"crossref","unstructured":"Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood. 2003;101:791\u2013800.","DOI":"10.1182\/blood-2002-07-1975"},{"key":"2020021215281213800_R89","unstructured":"Styles LA. Hemoglobin H-Constant Spring disease: an under recognized, severe form of \u03b1 thalassemia. J Pediatr Hematol\/Oncol. 1997;4:69\u201374."},{"key":"2020021215281213800_R90","doi-asserted-by":"crossref","unstructured":"Schrier SL, Bunyaratvej A, Khuhapinant A, et al. The unusual pathobiology of hemoglobin constant spring red blood cells. Blood. 1997;89:1762\u20131769.","DOI":"10.1182\/blood.V89.5.1762"},{"key":"2020021215281213800_R91","doi-asserted-by":"crossref","unstructured":"Pootrakul P, Sirankapracha P, Hemsorach S, et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia. Blood. 2000;96:2606\u20132612.","DOI":"10.1182\/blood.V96.7.2606"},{"key":"2020021215281213800_R92","doi-asserted-by":"crossref","unstructured":"Singer ST, Styles L, Bojanowski J, Quirolo K, Foote D, Vichinsky EP. Changing outcome of homozygous alpha-thalassemia: cautious optimism. J Pediatr Hematol Oncol. 2000;22:539\u2013542.","DOI":"10.1097\/00043426-200011000-00014"},{"key":"2020021215281213800_R93","doi-asserted-by":"crossref","unstructured":"Ng PC, Fok TF, Lee CH, et al. Is homozygous alpha-thalassaemia a lethal condition in the 1990s? Acta Paediatr. 1998;87:1197\u20131199.","DOI":"10.1111\/j.1651-2227.1998.tb00931.x"},{"key":"2020021215281213800_R94","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E\/beta-thalassemia: a consequence of splenectomy. Int J Hematol. 2003;77:299\u2013303.","DOI":"10.1007\/BF02983790"},{"key":"2020021215281213800_R95","unstructured":"Das N, Chowdhury TD, Chattopadhyay A, Datta AG. Attenuation of oxidative stress-induced changes in thalassemic erythrocytes by vitamin E. Pol J Pharmacol. 2004;56:85\u201396."},{"key":"2020021215281213800_R96","doi-asserted-by":"crossref","unstructured":"Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99:36\u201343.","DOI":"10.1182\/blood.V99.1.36"},{"key":"2020021215281213800_R97","doi-asserted-by":"crossref","unstructured":"Fucharoen G, Tungwiwat W, Ratanasiri T, Sanchaisuriya K, Fucharoen S. Prenatal detection of fetal hemoglobin E gene from maternal plasma. Prenat Diagn. 2003;23:393\u2013396.","DOI":"10.1002\/pd.607"},{"key":"2020021215281213800_R98","doi-asserted-by":"crossref","unstructured":"Waye JS, Eng B, Patterson M, et al. Hemoglobin H (Hb H) disease in Canada: molecular diagnosis and review of 116 cases. Am J Hematol. 2001;68:11\u201315.","DOI":"10.1002\/ajh.1142"},{"key":"2020021215281213800_R99","unstructured":"WHO. Guidelines for the control of haemoglobin disorders. Report of the VIth Annual Meeting of the WHO Working Group on Haemoglobinopathies, Cagliairi, Sardinia, 8\u20139 April 1989. World Health Organization, Geneva. 1994."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/14\/1634495\/014_034ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/14\/1634495\/014_034ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T15:29:24Z","timestamp":1581521364000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2004\/1\/14\/18690\/Thalassemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2004.1.14","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}